explore -WSS

explore

author：focus 2025-08-12 11:28:16 - browse：9559

BRENDAN SMIALOWSKI/AFP via Getty Images

A New York jury on Wednesday convicted the former CEO of Stimwave, a company that sold devices with dummy pieces of plastic, on two counts of health care fraud. The maximum jail sentence for each count is 20 years.

Laura Perryman led Stimwave, which sold nerve stimulation devices to combat pain, from 2010 to 2019. Under her leadership, Stimwave distorted the design of the device to better fit insurance codes, resulting in unnecessary plastic components that allowed the company to sell its products for thousands of dollars more than it otherwise could. From 2017 to 2020, the company sold nearly 8,000 devices with the non-functioning component.

STAT published new details about the Stimwave story last May, after former employees described how Perryman broke into Stimwave’s Florida headquarters to steal back devices after her termination in 2019. The fraud laid bare the limits of the Food and Drug Administration’s device surveillance system, doctors’ ability to scrutinize device effectiveness, and how impossible it is for patients to get answers about the implants they receive.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Cigna, Humana reportedly in talks to merge

entertainment

WSS

eGenesis tests gene

Flagship Pioneering launches a new biotech in two countries

With clinical trial data readouts, here's how to spot spin

Parkinson’s finding may lead to tests and, someday, treatments

AI generated plenty of interest at JPM but not a lot of trust

Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

Wikipedia

explore

entertainment

Medical records are filled with copy

FDA investigates CAR

The high cost of giving birth even with insurance

Medicare Advantage today, explained in one chart

Sports medicine is finally prioritizing gender equality

Mayo Clinic plans $5B tech

Jerome Adams on the need for new antivirals for Covid

As biotech industry slumps, bioscience job market is upside down

Trump demands the U.S. pay no more for drugs than other countries … again

Think you might have Covid

hotspot

30 years of 'Listening to Prozac'

NIH director takes cautious approach to Biden drug pricing priority

AI generated plenty of interest at JPM but not a lot of trust

Readout Newsletter: BridgeBio, Madrigal, and Silicon Valley Bank

Research misconduct: Proposed new rules face resistance

Flagship Pioneering launches a new biotech in two countries

hotspot

entertainment

knowledge

focus